[ad_1]

What happened

Actions of BioNTech (NASDAQ: BNTX) were down nearly 7% today after two studies involving more than 50,000 patients in the Mayo Clinic health system found a rival Modern‘s (NASDAQ: mRNA) The vaccine may be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.

The efficacy of BioNTech’s vaccine, developed with Pfizer (NYSE: PFE), was only 42% in July, according to the study, against 76% for Moderna. The numbers were calculated at a time when delta became the dominant strain infecting Americans. A second study showed that residents of nursing homes generated stronger immune responses after the Moderna vaccine than after that from BioNTech.

Image source: Getty Images.

So what

With so many Americans already vaccinated, the study won’t have as much of an impact as it might have had it released earlier this year. Still, this could influence those who aren’t vaccinated to seek out the Moderna jab rather than the BioNTech jab. There are still over 700,000 vaccinations a day, enough to move the needle financially.

Now what

It can also impact the demand for boosters. Despite the hesitations of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is no doubt that additional injections to maintain immunity will be needed. It has been reported that agencies may clear them for the 7 million immunocompromised Americans as early as this month.

Today’s decision couldn’t be limited to data, however. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go through peer review. Currently, Moderna and BioNTech are forecasting $ 20 billion and $ 18.6 billion in vaccine revenue, respectively, this year.

This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are heterogeneous! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.

[ad_2]

Source link

[ad_1]

What happened

Actions of BioNTech (NASDAQ: BNTX) were down nearly 7% today after two studies involving more than 50,000 patients in the Mayo Clinic health system found a rival Modern‘s (NASDAQ: mRNA) The vaccine may be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.

The efficacy of BioNTech’s vaccine, developed with Pfizer (NYSE: PFE), was only 42% in July, according to the study, against 76% for Moderna. The numbers were calculated at a time when delta became the dominant strain infecting Americans. A second study showed that residents of nursing homes generated stronger immune responses after the Moderna vaccine than after that from BioNTech.

Image source: Getty Images.

So what

With so many Americans already vaccinated, the study won’t have as much of an impact as it might have had it released earlier this year. Still, this could influence those who aren’t vaccinated to seek out the Moderna jab rather than the BioNTech jab. There are still over 700,000 vaccinations a day, enough to move the needle financially.

Now what

It can also impact the demand for boosters. Despite the hesitations of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is no doubt that additional injections to maintain immunity will be needed. It has been reported that agencies may clear them for the 7 million immunocompromised Americans as early as this month.

Today’s decision couldn’t be limited to data, however. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go through peer review. Currently, Moderna and BioNTech are forecasting $ 20 billion and $ 18.6 billion in vaccine revenue, respectively, this year.

This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are heterogeneous! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.

[ad_2]

Source link